Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer

Summary

The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1 monoclonal antibodies combined with platinum-based chemotherapy. The Phase II stage primarily aims to evaluate the efficacy of TQB6411 Injection in this same participants population.

Timeline

Start

2026-02-12

Primary completion

2026-09

Completion

2027-03

Drugs

Indications